Many Myelodysplastic Syndrome (MDS) patients struggle with low blood platelet counts, a condition called thrombocytopenia. Platelets help your blood clot, preventing excessive bleeding. When your platelet count drops below 150,000 per microliter (mcL), you're at a higher risk of bruising, bleeding episodes, and even internal bleeding or heart attack.
While anemia is more common in MDS, at least 10% of patients experience thrombocytopenia. Traditional treatments like platelet transfusions often provide only short-term relief, and patients can become resistant (disease recurrence) over time.
Eltrombopag, a medication currently undergoing clinical trials for low-risk MDS, offers new hope. It works by stimulating the production of platelets in your bone marrow. Studies have shown Eltrombopag to be safe and effective in:
A Phase 2 clinical trial (NCT02912208) investigated Eltrombopag's effectiveness for thrombocytopenia in MDS patients. Here are some encouraging results:
These findings suggest that Eltrombopag can be a well-tolerated and effective treatment for low-platelet MDS.
Eltrombopag is generally well-tolerated, but some side effects can occur. It's important to be aware of these and discuss them with your doctor.
Serious Side Effects:
Common Side Effects:
Eltrombopag offers a promising new approach for managing low platelet counts in MDS. Studies suggest it can effectively increase platelet production, reduce bleeding risk, and improve quality of life without worsening the underlying disease. Remember, Eltrombopag is still undergoing clinical trials, and more information may become available in the future.
To be up-to-date with this and similar MDS treatment advancements, make sure to sign up for our newsletter!
Source:
Many Myelodysplastic Syndrome (MDS) patients struggle with low blood platelet counts, a condition called thrombocytopenia. Platelets help your blood clot, preventing excessive bleeding. When your platelet count drops below 150,000 per microliter (mcL), you're at a higher risk of bruising, bleeding episodes, and even internal bleeding or heart attack.
While anemia is more common in MDS, at least 10% of patients experience thrombocytopenia. Traditional treatments like platelet transfusions often provide only short-term relief, and patients can become resistant (disease recurrence) over time.
Eltrombopag, a medication currently undergoing clinical trials for low-risk MDS, offers new hope. It works by stimulating the production of platelets in your bone marrow. Studies have shown Eltrombopag to be safe and effective in:
A Phase 2 clinical trial (NCT02912208) investigated Eltrombopag's effectiveness for thrombocytopenia in MDS patients. Here are some encouraging results:
These findings suggest that Eltrombopag can be a well-tolerated and effective treatment for low-platelet MDS.
Eltrombopag is generally well-tolerated, but some side effects can occur. It's important to be aware of these and discuss them with your doctor.
Serious Side Effects:
Common Side Effects:
Eltrombopag offers a promising new approach for managing low platelet counts in MDS. Studies suggest it can effectively increase platelet production, reduce bleeding risk, and improve quality of life without worsening the underlying disease. Remember, Eltrombopag is still undergoing clinical trials, and more information may become available in the future.
To be up-to-date with this and similar MDS treatment advancements, make sure to sign up for our newsletter!
Source:
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.